Free Trial
NASDAQ:PHXM

PHAXIAM Therapeutics (PHXM) Stock Price, News & Analysis

PHAXIAM Therapeutics logo
$3.10 0.00 (0.00%)
(As of 12/24/2024 ET)

About PHAXIAM Therapeutics Stock (NASDAQ:PHXM)

Key Stats

Today's Range
$3.10
$3.10
50-Day Range
$3.10
$3.10
52-Week Range
$2.50
$13.00
Volume
N/A
Average Volume
2,472 shs
Market Capitalization
$10.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Receive PHXM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAXIAM Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PHXM Stock News Headlines

How Low-Cost Stocks Generate Monthly Income
Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!
PHAXIAM Reports Third-Quarter 2024 Financial Information
PHAXIAM Therapeutics S.A. (PHXM.PA)
See More Headlines

PHXM Stock Analysis - Frequently Asked Questions

PHAXIAM Therapeutics' stock was trading at $4.44 at the beginning of the year. Since then, PHXM shares have decreased by 30.2% and is now trading at $3.10.
View the best growth stocks for 2024 here
.

PHAXIAM Therapeutics's stock reverse split on the morning of Wednesday, September 20th 2023. The 1-10 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of PHXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that PHAXIAM Therapeutics investors own include Salesforce (CRM), AbbVie (ABBV), Bank of America (BAC), Chevron (CVX), Merck & Co., Inc. (MRK), The PNC Financial Services Group (PNC) and AGCO (AGCO).

Company Calendar

Today
12/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHXM
Employees
49
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$32.66 million
Book Value
$7.98 per share

Miscellaneous

Free Float
3,346,000
Market Cap
$10.58 million
Optionable
No Data
Beta
2.35
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:PHXM) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners